{"slug":"vip-glp-1","verification":{"valid":true,"entries":2,"head":"2f11e481e6a32019b0c91774b7950c53d500540f22a34f3b4c532b3f372a34dd"},"energy":{"passes":2,"tokens_in":38428,"tokens_out":2886,"tokens_total":41314,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"2f11e481e6a32019b0c91774b7950c53d500540f22a34f3b4c532b3f372a34dd"},"provenance":[{"ts":"2026-06-29T22:31:01.013Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Glp 1\nSlug: vip-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\",\"**Therefore for you:** state whether this drug **reduces load**, **suppresses a signal**, or **supports metabolism** — and whether that helps or trades off repair for your condition.\"],\"prose\":\"1. **Drug:** GLP-1 agonists (class)\\n2. **What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\\n3. **Therefore for you:** state whether this drug **re","response":"{\n  \"slug\": \"vip-glp-1\",\n  \"title\": \"VIP Peptide in the Context of GLP-1 Agonists: Layered Evidence on Immune, Autonomic, and Metabolic Pathways\",\n  \"body\": \"## What's breaking down\\n\\nDegeneration in metabolic, gut motility, and immune signaling pathways can outpace repair when GLP-1 agonists are in use. Rapid weight loss from these drugs reduces mechanical stress on tissues but can also slow gastric emptying and contribute to muscle loss. VIP (vasoactive intestinal peptide) is discussed in research for its roles in autonomic regulation and immune modulation. If immune or autonomic layers are part of the picture, the focus stays on potential repair pathways rather than symptom masking.\\n\\n## Why VIP might help you\\n\\n1. VIP binds VPAC receptors found in gut, immune cells, and neural tissue.\\n2. If your autonomic or immune signaling shows imbalance, research examines VIP for tissue-level effects.\\n3. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\n1. Drug: GLP-1 agonists (class).\\n2. What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\\n3. Therefore for you: This drug reduces load through weight loss (approximately 4 lb lumbar compressive force per 1 lb lost) and supports metabolism, but may trade off repair by slowing gastric emptying or contributing to lean mass loss.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile. VIP targets immune / autonomic layers while GLP-1 agonists address metabolic load reduction. The two operate on distinct degeneration layers without direct overlap in the available data.\\n\\n## What the evidence actually shows\\n\\nHuman data on VIP remain limited to small trials. One study of eight patients with primary pulmonary hypertension used in","tokens_in":38428,"tokens_out":2886,"cost":0,"prev":"genesis","hash":"fe52b7218f24084c442fe030628a6210ce1664fe4079a16fea7eff242ed81002"},{"ts":"2026-07-17T02:43:23.845Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-glp-1","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fe52b7218f24084c442fe030628a6210ce1664fe4079a16fea7eff242ed81002","hash":"2f11e481e6a32019b0c91774b7950c53d500540f22a34f3b4c532b3f372a34dd"}]}